Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI-Powered symptom watch aims to keep head and neck cancer patients out of the ER

NCT ID NCT05338905

Symptom relief Sponsor: Roswell Park Cancer Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether using machine learning to closely monitor symptoms can help head and neck cancer patients avoid urgent hospital visits during radiation therapy. Researchers will compare intensive symptom tracking plus standard care to standard care alone in 72 patients with non-metastatic head and neck cancer. The goal is to see if early detection of worsening symptoms leads to better quality of life and fewer emergency visits.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Intensive symptom surveillance with machine learning risk stratification
What this could lead to
If successful, this approach could help doctors catch worsening symptoms earlier and reduce the need for emergency hospital visits during radiation therapy.
What could go wrong
This is a small, early-stage study (72 participants) focused on non-metastatic disease, so results may not apply to all head and neck cancer patients. The intervention is observational and does not test a new drug or treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

72 people

The number who actually took part.

Started

Oct 2022

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * PATIENTS: Age \>= 18 years of age * PATIENTS: Diagnosed with biopsy-proven, non-metastatic squamous cell carcinoma of head and neck * PATIENTS: Scheduled to start curative-intent radiation therapy within 4 weeks * PATIENTS: Able to provide informed consent in English * PATIENTS: Able to read and write in English * PATIENTS: Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related assessment * PATIENTS' INFORMED CAREGIVER (e.g. family members, friends): They are verbally identified by eligible patients as a caregiver * PATIENTS' INFORMED CAREGIVER (e.g. family members, friends): They are not receiving any payment to provide care for patients * PATIENTS' INFORMED CAREGIVER (e.g. family members, friends): Able to provide informed consent in English * PATIENTS' INFORMED CAREGIVER (e.g. family members, friends): Able to read and write in English Exclusion Criteria: * PATIENTS: Diagnosed with metastatic head and neck cancer * PATIENTS: Eligible for palliative-intent radiation therapy only * PATIENTS: Pregnant female participants * PATIENTS: Unwilling or unable to follow protocol requirements * PATIENTS: Any condition which in the Investigator's opinion deems the participant an unsuitable candidate

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Head and neck squamous cell carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

head and neck squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Head and neck squamous cell carcinoma

Contacts and locations

Locations

  • Roswell Park Cancer Institute

    Buffalo, New York, 14263, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.